Literature DB >> 16286246

Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.

Kian-Huat Lim1, Christopher M Counter.   

Abstract

While tumors become addicted to oncogenes like Ras, the microenvironment in which tumor cells reside changes during tumorigenesis; the cells are surrounded initially by normal tissue and later by tumor tissue. Hence, we asked if Ras exerts its oncogenic effects through the same set of effectors during different stages of tumorigenesis. We now show in human cells that the Ras effector pathways MAPK, RalGEF, and PI3K are required to initiate tumor growth. Conversely, activation of the PI3K/AKT pathway replaced Ras once tumors formed, although other effectors were still activated independently of Ras, presumably by factors provided upon the establishment of a tumor microenvironment. Thus, as tumorigenesis progresses the addiction of cancers to their initiating oncogene is reduced to, at least in the case of Ras, the PI3K/AKT pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286246     DOI: 10.1016/j.ccr.2005.10.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  89 in total

Review 1.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

2.  Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion.

Authors:  Hezhe Lu; Jianglan Liu; Shujing Liu; Jingwen Zeng; Deqiang Ding; Russ P Carstens; Yusheng Cong; Xiaowei Xu; Wei Guo
Journal:  Dev Cell       Date:  2013-12-09       Impact factor: 12.270

3.  Laser-guided assembly of heterotypic three-dimensional living cell microarrays.

Authors:  G M Akselrod; W Timp; U Mirsaidov; Q Zhao; C Li; R Timp; K Timp; P Matsudaira; G Timp
Journal:  Biophys J       Date:  2006-08-04       Impact factor: 4.033

4.  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.

Authors:  Chaoxin Hu; Tikva Dadon; Venugopal Chenna; Shinichi Yabuuchi; Rajat Bannerji; Robert Booher; Peter Strack; Nilofer Azad; Barry D Nelkin; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2015-04-30       Impact factor: 6.261

5.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

6.  KRAS and YAP1 converge to regulate EMT and tumor survival.

Authors:  Diane D Shao; Wen Xue; Elsa B Krall; Arjun Bhutkar; Federica Piccioni; Xiaoxing Wang; Anna C Schinzel; Sabina Sood; Joseph Rosenbluh; Jong W Kim; Yaara Zwang; Thomas M Roberts; David E Root; Tyler Jacks; William C Hahn
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

7.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

Review 8.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 9.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 10.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.